Coumestrol

01/01/2017 - "However, the clear molecular mechanism of anticancer-activity of coumestrol in breast carcinoma has not been reported. "
11/01/2013 - "Coumestrol at 50μM resulted in 50% and 30% growth inhibition of human breast cancer MCF-7 and colorectal cancer HCT116 cells, respectively. "
01/01/2017 - "Therefore, the objective of this study was to investigate the copper-dependent cytotoxic action of coumestrol in human breast cancer MCF-7 cells. "
02/01/2018 - "The current focus of the work was to identify any possible role of copper in coumestrol cytotoxic action against breast cancer MDA-MB-231 cells. "
02/01/2018 - "Coumestrol, a phytoestrogen inhibits cell growth of ER-negative breast cancer MDA-MB-231 cells; the exact mechanism has not yet been reported. "

08/01/2009 - "Although the effects of coumestrol on osteoblasts and osteoclasts can be summarized as increasing the bone density and preventing bone resorption, direct and detailed effects of coumestrol on bone marrow stromal cells remain obscure. "
07/01/1995 - "Therefore, coumestrol is a unique substance in that it inhibits bone resorption and, at the same time, stimulates bone mineralization. "
03/01/1994 - "The effects of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoli ne-6-one (KCA-098), a derivative of coumestrol, on bone resorption was studied in organ cultures of 20-day fetal rat femora. "
04/15/2017 - "Our findings demonstrated that psoralidin and coumestrol exert their bone-protective effects by enhancing bone formation of osteoblasts and inhibiting bone resorption of osteoclasts. "
04/15/2017 - "Interestingly, psoralidin showed much stronger effects than coumestrol at enhancing osteoblast proliferation/differentiation or inhibiting osteoclast differentiation and bone resorption. "

04/01/2013 - "From 6.5 to 16.5 days post coitus and 1 to 13 days post partum (dpp), maternal mice were administered coumestrol at 200 μg/kg body weight/day. "
06/01/2012 - "From 6.5 to 16.5 days post coitus and from 3 to 10 days after parturition, maternal mice were administered at 200 µg/kg body weight/day of coumestrol. "
05/01/2011 - "From 6.5 to 16.5 days post coitus (dpc), pregnant mice were administered coumestrol at 200 µg/kg body weight/day. "
02/01/2008 - "From 6.5 to 16.5 days post coitus (dpc), pregnant females were administered daily doses of coumestrol (200 microg/kg body weight/day). "
11/01/1993 - "Coumestrol treatment did not significantly alter the time of vaginal opening, although vaginal opening did occur at a lighter body weight. "

09/20/2012 - "Coumestrol has neuroprotective effects before and after global cerebral ischemia in female rats."
03/01/2014 - "Coumestrol treatment was effective in preventing neuronal loss in all times of administration as well as able to rescue the Na+, K+ -ATPase activity, suggesting its potential benefits for either prevention or therapeutics use against cerebral ischemia in males."

09/01/2020 - "Coumestrol ameliorates doxorubicin-induced cardiotoxicity via activating AMPKα."